Health & FitnessLife

Intas launches the World’s First SB-100mg Itraconazole

0

One of the world’s leading pharmaceutical companies, Intas Pharmaceuticals, has made a progressive breakthrough in the Antifungal Therapy domain with the launch of the world’s first Super Bioavailable Itraconazole-SB 100mg by the Brand Name of Itaspor-SB Forte/Subawin. It has been recently approved by Indian Regulatory Authorities.

Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage, antacids consumption etc. and overall cost of treatment. 

Join the "The Future of PR" newsletter to be invited to exclusive events!

Enter your email to receive our newsletter.

The Future of PR: Real information, that you can use!

Itaspor SB Forte/Subawin is expected to improve patient compliance and reduce the Doctor’s counseling time. It will reduce dosing to half. Furthermore, patients can take it with or without a meal with just water or as directed by the physician. The cost of the therapy is also reduced substantially. 

TheFutureOfPR.com is powered by Atharva Marcom Public Relations – India’s smartest public relations

As per published literature and clinicians’ experience, the Itraconazole molecule has low blood drug concentration, affecting safety and efficacy when taken orally. These blood levels highly vary from patient to patient. Moreover, the recommendation to take it with a full fatty meal and an acidic beverage further reduces patient compliance and adds to the problem of desired blood drug concentration. Another factor is the cost of therapy for fungal infection patients, as treatment duration varies from 3 to 8 weeks.

Intas’ newest formulation within the 25 year old brand Itaspor is formulated with Super Bioavailable (SB) Technology that makes 1 Itaspor-SB Forte capsule equivalent to conventional 200mg Itraconazole,” said Dr Alok Chaturvedi, Senior Vice-president & Head – Medical Affairs, Intas Pharmaceuticals.

“Given the benefits of Super Bioavailable (SB) Technology like half the drug, no inter-patient variability, freedom to prescribe with/without food, any beverage, even with Antacids, and that too with the reduction in overall treatment cost certainly seems to be a win-win proposition,” said Dr R D Kharkar, Senior Consultant Dermatologist, Mumbai.

Subscribe to TheFutureOfPR.com to get great ideas on lifeeducationhealth & fitnessreal estateglamourjewelrymovies, and podcasts! Share this article with people who you think might benefit. They will thank you for it!

TFPR Editorial

Impetus recognized as Asia’s Dream Employer of the year for the 5th time

Previous article

Real Estate CRM provider Sell.Do, commits to empower the developers and brokers of Bangalore

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *